Serveur d'exploration sur l'automédication dans le monde francophone

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Qualitative study of patients' decision-making when accepting second-line treatment after failure of first-line chemotherapy.

Identifieur interne : 000812 ( Main/Exploration ); précédent : 000811; suivant : 000813

Qualitative study of patients' decision-making when accepting second-line treatment after failure of first-line chemotherapy.

Auteurs : Jean-Louis Pujol [France] ; Benoît Roch [France] ; Caroline Roth [France] ; Jean-Pierre Mérel [France]

Source :

RBID : pubmed:29799879

Descripteurs français

English descriptors

Abstract

OBJECTIVE

Treatment failures in advanced lung cancer are frequent events affecting patients during or after first-line chemotherapy. International guidelines recommend second-line chemotherapy. However, around one half of patients who experience disease progression enter a systemic second-line therapy. In the herein qualitative study, we investigated patients' thoughts and attitudes determining the decision to undergo a second-line chemotherapy.

METHODS

Thirty-three purposively selected patients who recently accepted second-line or palliative chemotherapy were invited to participate in this survey consisting of semi-structured in-depth interviews. Grounded theory was applied to investigate participants' perceptions of the context that have surrounded their decision to undergo palliative chemotherapy.

RESULTS

For most patients, tumor burden and reduced quality of life in relation with lung cancer itself were major drivers of the decision-making process. There was a balance between two different attitudes: making a decision to undergo a new line of chemotherapy or starting a psychological process in order to accept end of life. Choosing between these two attitudes allowed the patient to keep the matter of palliative care at a distance. Even in case of low chance of success, many patients who worried about their life partner's future would accept a new chemotherapy line. Some patients experienced ambivalent thoughts regarding social network, particularly about their family as daily function impairment required an increased need for relative's support. The initial "Worrying about others" thoughts left place to in an increasing self-need of care as those provided by relatives; this phenomenon might increase patients' self- perception of being a burden for others. Confidence previously established with formal caregiver support was another major decision driver: some patients with sustained confidence in their medical staff may have privileged this formal support rather than family support when the latter was perceived as weak, insufficient or intrusive.

CONCLUSION

This study identified three domains involved into a complex interplay for lung cancer patients' decision regarding second-line palliative chemotherapy: (i) perception of the definitive loss of health, (ii) interactions between idiosyncrasy (hope, disease burden) and environment (healthcare and social network support), and (iii) patient's subjective evaluation of chemotherapy benefit-risk.


DOI: 10.1371/journal.pone.0197605
PubMed: 29799879
PubMed Central: PMC5969734


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Qualitative study of patients' decision-making when accepting second-line treatment after failure of first-line chemotherapy.</title>
<author>
<name sortKey="Pujol, Jean Louis" sort="Pujol, Jean Louis" uniqKey="Pujol J" first="Jean-Louis" last="Pujol">Jean-Louis Pujol</name>
<affiliation wicri:level="1">
<nlm:affiliation>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex</wicri:regionArea>
<wicri:noRegion>Montpellier Cedex</wicri:noRegion>
<wicri:noRegion>Montpellier Cedex</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>Epsylon: Interdisciplinary properties and property dimensions concurring to patients' decision making about subsequent line of chemotherapy research unit dedicated to human sciences and health, EA 4556, Université Paul Valéry Rue du Pr. Henri Serre, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Epsylon: Interdisciplinary properties and property dimensions concurring to patients' decision making about subsequent line of chemotherapy research unit dedicated to human sciences and health, EA 4556, Université Paul Valéry Rue du Pr. Henri Serre, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Roch, Benoit" sort="Roch, Benoit" uniqKey="Roch B" first="Benoît" last="Roch">Benoît Roch</name>
<affiliation wicri:level="1">
<nlm:affiliation>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex</wicri:regionArea>
<wicri:noRegion>Montpellier Cedex</wicri:noRegion>
<wicri:noRegion>Montpellier Cedex</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Roth, Caroline" sort="Roth, Caroline" uniqKey="Roth C" first="Caroline" last="Roth">Caroline Roth</name>
<affiliation wicri:level="1">
<nlm:affiliation>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex</wicri:regionArea>
<wicri:noRegion>Montpellier Cedex</wicri:noRegion>
<wicri:noRegion>Montpellier Cedex</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Merel, Jean Pierre" sort="Merel, Jean Pierre" uniqKey="Merel J" first="Jean-Pierre" last="Mérel">Jean-Pierre Mérel</name>
<affiliation wicri:level="1">
<nlm:affiliation>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex</wicri:regionArea>
<wicri:noRegion>Montpellier Cedex</wicri:noRegion>
<wicri:noRegion>Montpellier Cedex</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:29799879</idno>
<idno type="pmid">29799879</idno>
<idno type="doi">10.1371/journal.pone.0197605</idno>
<idno type="pmc">PMC5969734</idno>
<idno type="wicri:Area/Main/Corpus">000832</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000832</idno>
<idno type="wicri:Area/Main/Curation">000832</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000832</idno>
<idno type="wicri:Area/Main/Exploration">000832</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Qualitative study of patients' decision-making when accepting second-line treatment after failure of first-line chemotherapy.</title>
<author>
<name sortKey="Pujol, Jean Louis" sort="Pujol, Jean Louis" uniqKey="Pujol J" first="Jean-Louis" last="Pujol">Jean-Louis Pujol</name>
<affiliation wicri:level="1">
<nlm:affiliation>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex</wicri:regionArea>
<wicri:noRegion>Montpellier Cedex</wicri:noRegion>
<wicri:noRegion>Montpellier Cedex</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>Epsylon: Interdisciplinary properties and property dimensions concurring to patients' decision making about subsequent line of chemotherapy research unit dedicated to human sciences and health, EA 4556, Université Paul Valéry Rue du Pr. Henri Serre, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Epsylon: Interdisciplinary properties and property dimensions concurring to patients' decision making about subsequent line of chemotherapy research unit dedicated to human sciences and health, EA 4556, Université Paul Valéry Rue du Pr. Henri Serre, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Roch, Benoit" sort="Roch, Benoit" uniqKey="Roch B" first="Benoît" last="Roch">Benoît Roch</name>
<affiliation wicri:level="1">
<nlm:affiliation>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex</wicri:regionArea>
<wicri:noRegion>Montpellier Cedex</wicri:noRegion>
<wicri:noRegion>Montpellier Cedex</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Roth, Caroline" sort="Roth, Caroline" uniqKey="Roth C" first="Caroline" last="Roth">Caroline Roth</name>
<affiliation wicri:level="1">
<nlm:affiliation>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex</wicri:regionArea>
<wicri:noRegion>Montpellier Cedex</wicri:noRegion>
<wicri:noRegion>Montpellier Cedex</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Merel, Jean Pierre" sort="Merel, Jean Pierre" uniqKey="Merel J" first="Jean-Pierre" last="Mérel">Jean-Pierre Mérel</name>
<affiliation wicri:level="1">
<nlm:affiliation>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex</wicri:regionArea>
<wicri:noRegion>Montpellier Cedex</wicri:noRegion>
<wicri:noRegion>Montpellier Cedex</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series>
<title level="j">PloS one</title>
<idno type="eISSN">1932-6203</idno>
<imprint>
<date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Aged (MeSH)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Decision Making (MeSH)</term>
<term>Disease Progression (MeSH)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Lung Neoplasms (drug therapy)</term>
<term>Lung Neoplasms (psychology)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Palliative Care (MeSH)</term>
<term>Patient Acceptance of Health Care (MeSH)</term>
<term>Patient Participation (MeSH)</term>
<term>Perception (MeSH)</term>
<term>Quality of Life (MeSH)</term>
<term>Social Support (MeSH)</term>
<term>Surveys and Questionnaires (MeSH)</term>
<term>Treatment Failure (MeSH)</term>
<term>Tumor Burden (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Acceptation des soins par les patients (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Charge tumorale (MeSH)</term>
<term>Enquêtes et questionnaires (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Participation des patients (MeSH)</term>
<term>Perception (MeSH)</term>
<term>Prise de décision (MeSH)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Qualité de vie (MeSH)</term>
<term>Soins palliatifs (MeSH)</term>
<term>Soutien social (MeSH)</term>
<term>Sujet âgé (MeSH)</term>
<term>Tumeurs du poumon (psychologie)</term>
<term>Tumeurs du poumon (traitement médicamenteux)</term>
<term>Échec thérapeutique (MeSH)</term>
<term>Évolution de la maladie (MeSH)</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="psychologie" xml:lang="fr">
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en">
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en">
<term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Aged</term>
<term>Decision Making</term>
<term>Disease Progression</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Palliative Care</term>
<term>Patient Acceptance of Health Care</term>
<term>Patient Participation</term>
<term>Perception</term>
<term>Quality of Life</term>
<term>Social Support</term>
<term>Surveys and Questionnaires</term>
<term>Treatment Failure</term>
<term>Tumor Burden</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Acceptation des soins par les patients</term>
<term>Adulte d'âge moyen</term>
<term>Charge tumorale</term>
<term>Enquêtes et questionnaires</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Participation des patients</term>
<term>Perception</term>
<term>Prise de décision</term>
<term>Qualité de vie</term>
<term>Soins palliatifs</term>
<term>Soutien social</term>
<term>Sujet âgé</term>
<term>Échec thérapeutique</term>
<term>Évolution de la maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>
<b>OBJECTIVE</b>
</p>
<p>Treatment failures in advanced lung cancer are frequent events affecting patients during or after first-line chemotherapy. International guidelines recommend second-line chemotherapy. However, around one half of patients who experience disease progression enter a systemic second-line therapy. In the herein qualitative study, we investigated patients' thoughts and attitudes determining the decision to undergo a second-line chemotherapy.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>METHODS</b>
</p>
<p>Thirty-three purposively selected patients who recently accepted second-line or palliative chemotherapy were invited to participate in this survey consisting of semi-structured in-depth interviews. Grounded theory was applied to investigate participants' perceptions of the context that have surrounded their decision to undergo palliative chemotherapy.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>RESULTS</b>
</p>
<p>For most patients, tumor burden and reduced quality of life in relation with lung cancer itself were major drivers of the decision-making process. There was a balance between two different attitudes: making a decision to undergo a new line of chemotherapy or starting a psychological process in order to accept end of life. Choosing between these two attitudes allowed the patient to keep the matter of palliative care at a distance. Even in case of low chance of success, many patients who worried about their life partner's future would accept a new chemotherapy line. Some patients experienced ambivalent thoughts regarding social network, particularly about their family as daily function impairment required an increased need for relative's support. The initial "Worrying about others" thoughts left place to in an increasing self-need of care as those provided by relatives; this phenomenon might increase patients' self- perception of being a burden for others. Confidence previously established with formal caregiver support was another major decision driver: some patients with sustained confidence in their medical staff may have privileged this formal support rather than family support when the latter was perceived as weak, insufficient or intrusive.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>CONCLUSION</b>
</p>
<p>This study identified three domains involved into a complex interplay for lung cancer patients' decision regarding second-line palliative chemotherapy: (i) perception of the definitive loss of health, (ii) interactions between idiosyncrasy (hope, disease burden) and environment (healthcare and social network support), and (iii) patient's subjective evaluation of chemotherapy benefit-risk.</p>
</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">29799879</PMID>
<DateCompleted>
<Year>2018</Year>
<Month>12</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection">
<Journal>
<ISSN IssnType="Electronic">1932-6203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>13</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2018</Year>
</PubDate>
</JournalIssue>
<Title>PloS one</Title>
<ISOAbbreviation>PLoS One</ISOAbbreviation>
</Journal>
<ArticleTitle>Qualitative study of patients' decision-making when accepting second-line treatment after failure of first-line chemotherapy.</ArticleTitle>
<Pagination>
<MedlinePgn>e0197605</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0197605</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE">Treatment failures in advanced lung cancer are frequent events affecting patients during or after first-line chemotherapy. International guidelines recommend second-line chemotherapy. However, around one half of patients who experience disease progression enter a systemic second-line therapy. In the herein qualitative study, we investigated patients' thoughts and attitudes determining the decision to undergo a second-line chemotherapy.</AbstractText>
<AbstractText Label="METHODS">Thirty-three purposively selected patients who recently accepted second-line or palliative chemotherapy were invited to participate in this survey consisting of semi-structured in-depth interviews. Grounded theory was applied to investigate participants' perceptions of the context that have surrounded their decision to undergo palliative chemotherapy.</AbstractText>
<AbstractText Label="RESULTS">For most patients, tumor burden and reduced quality of life in relation with lung cancer itself were major drivers of the decision-making process. There was a balance between two different attitudes: making a decision to undergo a new line of chemotherapy or starting a psychological process in order to accept end of life. Choosing between these two attitudes allowed the patient to keep the matter of palliative care at a distance. Even in case of low chance of success, many patients who worried about their life partner's future would accept a new chemotherapy line. Some patients experienced ambivalent thoughts regarding social network, particularly about their family as daily function impairment required an increased need for relative's support. The initial "Worrying about others" thoughts left place to in an increasing self-need of care as those provided by relatives; this phenomenon might increase patients' self- perception of being a burden for others. Confidence previously established with formal caregiver support was another major decision driver: some patients with sustained confidence in their medical staff may have privileged this formal support rather than family support when the latter was perceived as weak, insufficient or intrusive.</AbstractText>
<AbstractText Label="CONCLUSION">This study identified three domains involved into a complex interplay for lung cancer patients' decision regarding second-line palliative chemotherapy: (i) perception of the definitive loss of health, (ii) interactions between idiosyncrasy (hope, disease burden) and environment (healthcare and social network support), and (iii) patient's subjective evaluation of chemotherapy benefit-risk.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pujol</LastName>
<ForeName>Jean-Louis</ForeName>
<Initials>JL</Initials>
<Identifier Source="ORCID">0000-0001-9465-0693</Identifier>
<AffiliationInfo>
<Affiliation>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Epsylon: Interdisciplinary properties and property dimensions concurring to patients' decision making about subsequent line of chemotherapy research unit dedicated to human sciences and health, EA 4556, Université Paul Valéry Rue du Pr. Henri Serre, Montpellier, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Roch</LastName>
<ForeName>Benoît</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Roth</LastName>
<ForeName>Caroline</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mérel</LastName>
<ForeName>Jean-Pierre</ForeName>
<Initials>JP</Initials>
<AffiliationInfo>
<Affiliation>Thoracic oncology Unit Hôpital Universitaire Arnaud de Villeneuve, Montpellier Cedex, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2018</Year>
<Month>05</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>PLoS One</MedlineTA>
<NlmUniqueID>101285081</NlmUniqueID>
<ISSNLinking>1932-6203</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003657" MajorTopicYN="Y">Decision Making</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010166" MajorTopicYN="N">Palliative Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010358" MajorTopicYN="Y">Patient Participation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010465" MajorTopicYN="N">Perception</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012944" MajorTopicYN="N">Social Support</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2017</Year>
<Month>06</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2018</Year>
<Month>05</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2018</Year>
<Month>5</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2018</Year>
<Month>5</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2018</Year>
<Month>12</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">29799879</ArticleId>
<ArticleId IdType="doi">10.1371/journal.pone.0197605</ArticleId>
<ArticleId IdType="pii">PONE-D-17-23053</ArticleId>
<ArticleId IdType="pmc">PMC5969734</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Psychooncology. 2010 Sep;19(9):901-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20799373</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2012 Oct 25;367(17):1616-25</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23094723</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Qual Health Care. 2007 Dec;19(6):349-57</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17872937</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lung Cancer. 2006 Feb;51(2):159-72</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16360238</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Psychooncology. 2017 Jul;26(7):917-926</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">27440317</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Oncol Nurs. 2012 Apr;16(2):145-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21616716</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Thorac Oncol. 2018 May 10;:null</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">29753578</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res Treat. 2015 Oct;47(4):555-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25687851</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Adv Nurs. 2003 Nov;44(4):427-35</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14651715</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Cancer Res Clin Oncol. 2016 Jan;142(1):1-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25644862</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lung Cancer. 2004 Dec;46 Suppl 2:S41-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15698531</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Natl Cancer Inst. 2006 Aug 2;98(15):1053-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16882942</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2006 Jul 20;24(21):3490-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16849766</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMJ. 2011 Apr 04;342:d1933</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21464103</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Psychooncology. 2016 Jun;25(6):641-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26370620</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2007 May 20;25(15):2086-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17513814</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2008 Aug 10;26(23):3860-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18688053</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Psychooncology. 2017 Jun;26(6):793-799</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">27449209</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24399786</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Thorac Oncol. 2013 Aug;8(8):997-1003</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23787802</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2015 Oct 20;33(30):3488-515</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26324367</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2012 Feb 1;30(4):394-400</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22203758</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>France</li>
</country>
<region>
<li>Languedoc-Roussillon</li>
<li>Occitanie (région administrative)</li>
</region>
<settlement>
<li>Montpellier</li>
</settlement>
</list>
<tree>
<country name="France">
<noRegion>
<name sortKey="Pujol, Jean Louis" sort="Pujol, Jean Louis" uniqKey="Pujol J" first="Jean-Louis" last="Pujol">Jean-Louis Pujol</name>
</noRegion>
<name sortKey="Merel, Jean Pierre" sort="Merel, Jean Pierre" uniqKey="Merel J" first="Jean-Pierre" last="Mérel">Jean-Pierre Mérel</name>
<name sortKey="Pujol, Jean Louis" sort="Pujol, Jean Louis" uniqKey="Pujol J" first="Jean-Louis" last="Pujol">Jean-Louis Pujol</name>
<name sortKey="Roch, Benoit" sort="Roch, Benoit" uniqKey="Roch B" first="Benoît" last="Roch">Benoît Roch</name>
<name sortKey="Roth, Caroline" sort="Roth, Caroline" uniqKey="Roth C" first="Caroline" last="Roth">Caroline Roth</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000812 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000812 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    AutomedicationFrancoV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:29799879
   |texte=   Qualitative study of patients' decision-making when accepting second-line treatment after failure of first-line chemotherapy.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:29799879" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a AutomedicationFrancoV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Mon Mar 15 15:24:36 2021. Site generation: Mon Mar 15 15:32:03 2021